Stockscreener 앱 받기
72.30
0.47%
-0.34
전일 마감가:
$72.64
열려 있는:
$73.03
하루 거래량:
1.60M
Relative Volume:
0.79
시가총액:
$12.67B
수익:
$342.96M
순이익/손실:
$-864.29M
주가수익비율:
-13.03
EPS:
-5.55
순현금흐름:
$-636.03M
1주 성능:
+3.75%
1개월 성능:
-1.55%
6개월 성능:
+5.83%
1년 성능:
+181.76%
1일 변동 폭
$71.95
$73.39
1주일 범위
$69.18
$73.39
52주 변동 폭
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
72.30 | 12.67B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline - Yahoo Finance
Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential - Insider Monkey
Insmed To Present at the BofA Securities 2025 Health Care Conference - GuruFocus
Insmed To Present at the BofA Securities 2025 Health Care Conference | INSM Stock News - GuruFocus
Insmed Inc (INSM)’s Day in Review: Closing at 69.69, Up by 1.06 - DWinneX
Gaining Ground: Insmed Inc (INSM) Closes Lower at 72.00, Down -5.62 - DWinneX
Top Medical Stocks To Watch Now – April 25th - Defense World
Insmed Inc [INSM] moved down -2.60: Why It’s Important - dbtnews.com
Could investigational drug become first-in-class bronchiectasis therapy? - marketscreener.com
Insmed: Poised For Transformation Beyond ARIKAYCE (NASDAQ:INSM) - Seeking Alpha
Insmed Inc [INSM] stock for 479,177 USD was sold by Lewis William - knoxdaily.com
Insmed’s (INSM) Buy Rating Reiterated at HC Wainwright - Defense World
Insmed Sees Unusually Large Options Volume (NASDAQ:INSM) - Defense World
Insmed Inc (INSM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Insmed Calls In Convertible Notes, Proposes Share Conversion - Finimize
Insmed to redeem $569.5 million convertible notes due 2028 By Investing.com - Investing.com Canada
Insmed Inc (NASDAQ:INSM) Rises 5.71% In 2025; Is It Still Attractive At $70.85? - Marketing Sentinel
INSM’s price-to-sales ratio: A comparative analysis with its peers - uspostnews.com
Insmed to Redeem $569.5 Million of Convertible Senior Notes - marketscreener.com
Insmed Announces Redemption of all $569.5 Million of Remaining O - GuruFocus
Insmed Flexes Financial Muscle with $569M Early Note Redemption: What it Means for Investors - Stock Titan
Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis | INSM Stock News - GuruFocus
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib in Treating Bronchiectasis | INSM Stock News - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - marketscreener.com
Insmed to Host First-Quarter 2025 Financial Results Conference C - GuruFocus
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 | INSM Stock News - GuruFocus
Insmed Q1 2025 Earnings Preview: What New Financial Metrics Will Shape Growth Strategy? - Stock Titan
H.C. Wainwright maintains Buy on Insmed stock with $90 target By Investing.com - Investing.com Canada
Cerity Partners LLC Sells 3,090 Shares of Insmed Incorporated (NASDAQ:INSM) - American Banking and Market News
Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Analysts - Defense World
Insmed CEO William Lewis sells $479,176 in stock By Investing.com - Investing.com Canada
Insmed CEO William Lewis sells $479,176 in stock - Investing.com Australia
New cathepsin C inhibitors disclosed in Insmed patent - BioWorld MedTech
Envestnet Asset Management Inc. Buys 15,227 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Wells Fargo & Company MN Buys 33,214 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - MarketScreener
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years - Benzinga
LPL Financial LLC Raises Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
Commit To Purchase Insmed At $50, Earn 13.9% Annualized Using Options - Nasdaq
Cantor Fitzgerald maintains Overweight on Insmed stock, bullish on TPIP By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Community Health (CYH) and Argenx Se (ARGX) - The Globe and Mail
Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey
10 Best Long Term Growth Stocks to Buy According to Billionaires - Insider Monkey
Form DEF 14A INSMED Inc For: May 15 - StreetInsider
Insmed CEO William Lewis sells $502,577 in stock By Investing.com - Investing.com India
Insmed CEO William Lewis sells $502,577 in stock - Investing.com Australia
Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025 - Insider Monkey
Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.63%
자본화:
|
볼륨(24시간):